Theron Pharmaceuticals Overview
- Year Founded
-
2008
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
Theron Pharmaceuticals General Information
Description
Operator of a biotechnology platform intended to develop long-acting M3 muscarinic antagonist drugs. The company's focus is on discovering drug agents for improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma, enabling healthcare professionals to offer novel combination therapies that offer improved convenience and clinical outcomes for asthma treatment practices.
Contact Information
Website
theronpharma.comCorporate Office
- 365 San Aleso Avenue
- Sunnyvale, CA 94085
- United States
Corporate Office
- 365 San Aleso Avenue
- Sunnyvale, CA 94085
- United States
Theron Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 01-Nov-2024 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC (Series B1) | 31-Jul-2015 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series B) | 19-May-2011 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 14-May-2010 | $1.14M | $1.14M | Completed | Pre-Clinical Trials | |
| 1. Grant | 01-Jan-2010 | $164K | Completed | Pre-Clinical Trials |
Theron Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Series A | 5,662,567 | $0.001000 | $0.03 | $0.36 | $0.36 | 1x | $0.36 | 29.78% |
Theron Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Theron Pharmaceuticals Patents
Theron Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-2973972-T3 | Compositions of 7-azoniabicyclo[2.2.1]heptane derivatives for dry powder inhalers | Active | 08-Jan-2016 | ||
| CA-3008292-A1 | Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives | Active | 08-Jan-2016 | ||
| EP-3400214-A1 | Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives | Active | 08-Jan-2016 | ||
| EP-3400214-A4 | Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives | Active | 08-Jan-2016 | ||
| EP-3400214-B1 | Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives | Active | 08-Jan-2016 | A61K31/40 |
Theron Pharmaceuticals FAQs
-
When was Theron Pharmaceuticals founded?
Theron Pharmaceuticals was founded in 2008.
-
Where is Theron Pharmaceuticals headquartered?
Theron Pharmaceuticals is headquartered in Sunnyvale, CA.
-
What industry is Theron Pharmaceuticals in?
Theron Pharmaceuticals’s primary industry is Biotechnology.
-
Is Theron Pharmaceuticals a private or public company?
Theron Pharmaceuticals is a Private company.
-
What is Theron Pharmaceuticals’s current revenue?
The current revenue for Theron Pharmaceuticals is .
-
How much funding has Theron Pharmaceuticals raised over time?
Theron Pharmaceuticals has raised $2.21M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
